Results 31 to 40 of about 19,315 (197)

Ticagrelor plasma concentration, metabolite ratio, and LDH level as independent risk factors for ticagrelor-induced dyspnea in ACS patients

Frontiers in Cardiovascular Medicine
IntroductionTicagrelor-induced dyspnea is a significant clinical concern and is associated with adverse outcomes. However, the specific risk factors leading to ticagrelor-induced dyspnea have not been fully elucidated.
Yazi Zhao, Yazi Zhao, Mengqi Gong, Yong Su, Yong Su, Jiaxin Zhao, Fangde Hong, Zheyuan Lu, Mengqing Ma, Meijie Jiang, Meijie Jiang, Youfeng Liang   +11 more
doaj   +1 more source

Ticagrelor With or Without Aspirin After Complex PCI. [PDF]

, 2020
BACKGROUND: Whether a regimen of ticagrelor monotherapy attenuates bleeding complications without increasing ischemic risk in patients undergoing complex percutaneous coronary intervention (PCI) is unknown.
Gibson, C. Michael, Pocock, Stuart, Giustino, Gennaro, Escaned, Javier, Shlofmitz, Richard, Witzenbichler, Bernhard, Briguori, Carlo, Sartori, Samantha, Dudek, Dariusz, Cohen, David J., Angiolillo, Dominick J., Sharma, Samin, Gibson, C Michael, Oldroyd, Keith, Dangas, George, Angiolillo, Dominick J, Kornowski, Ran, Chandiramani, Rishi, Kaul, Upendra, Huber, Kurt, Kunadian, Vijay, Ya-Ling, Han, Baber, Usman, Sardella, Gennaro, Cohen, David J, Collier, Timothy, Mehta, Shamir, Pocock, Stuart J., Mehran, Roxana   +28 more
core   +3 more sources

Appropriateness of Ticagrelor Use at Initiation: A Population-Based Cohort Study

Journal of Pharmacy & Pharmaceutical Sciences, 2018
Purpose. Ticagrelor is recommended following an acute coronary syndrome if used appropriately. Its use has not yet been well described in the context of ambulatory clinical practice.
Jean-Pierre Gregoire, Paul Poirier, Norma Pérez, Éric Demers, Jocelyne Moisan   +4 more
doaj   +1 more source

Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice

Molecules, 2021
Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. Ticagrelor antagonizes P2Y12 receptors, but recently, this effect on the central nervous system has been linked to the development of dyspnea ...
Jennifer Lagoutte-Renosi, Bernard Royer, Vahideh Rabani, Siamak Davani   +3 more
doaj   +1 more source

Novel cancer-fighting role of ticagrelor inhibits GTSE1-induced EMT by regulating PI3K/Akt/NF-κB signaling pathway in malignant glioma

Heliyon
Background: Glioma is the most common malignant brain tumor of the central nervous system. Despite of the improvement of therapeutic strategy, the prognosis of malignant glioma patients underwent by STUPP strategy is still unexpected.
Enzhou Lu, Boxian Zhao, Chao Yuan, Yanchao Liang, Xiaoxiong Wang, Guang Yang   +5 more
doaj   +1 more source

The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population [PDF]

PeerJ
Background Ticagrelor is a novel oral antiplatelet agent which can selectively inhibit P2Y12 receptor. Bleeding and dyspnea are common adverse reactions of ticagrelor in clinic.
Xiaoxia Hu, Peng Wang, Dali Zeng, Guo-xin Hu   +3 more
doaj   +2 more sources

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention [PDF]

, 2023
\ua9 2023 American College of Cardiology Foundation. Background: Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases.
Steg PG, Witzenbichler B, Gil R, Kunadian V, Cao D, Stefanini GG, Pocock S, Kaul U, Ielasi A, Moliterno DJ, Collier T, Huber K, Sardella G, Mehta S, Briguori C, Weisz G, Mehran R, Dudek D, Sartori S, Kornowski R, Sharma SK, Pivato CA, Ohman EM, Vogel B, Escaned J, Baber U, Angiolillo DJ, Dangas G, Zhang Z, Shlofmitz R, Krucoff MW, Gibson M, Cohen DJ   +32 more
core   +2 more sources

Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo. [PDF]

PLoS ONE, 2015
In patients with myocardial infarction, ticagrelor reduces cardiovascular and sepsis-related mortality, and can cause dyspnea. It is suggested that this is caused by adenosine receptor stimulation, because in preclinical studies, ticagrelor blocks the ...
T N A van den Berg, S El Messaoudi, G A Rongen, P H H van den Broek, A Bilos, A R T Donders, M E Gomes, N P Riksen   +7 more
doaj   +1 more source

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

Advanced Science, EarlyView.
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee, Chul‐Gyun Lim, Pothiappan Vairaprakash, Jong‐Min Kim, Jiyoon Kim, Ji‐Young Park, Klaus M. Hahn, Hyunbo Shim, Hae Woong Choi, Tobias S. Ulmer, Soon Jun Hong, Chungho Kim   +11 more
wiley   +1 more source

Ticagrelor Use in Stroke Patients: Past, Present, and Future

, 2021
Rahul Chandra, Harneel Saini, Russell Cerejo, Ashis Tayal, Konark Malhotra Department of Neurology, Allegheny Health Network, Pittsburgh, PA, USACorrespondence: Konark MalhotraDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USATel +1 ...
Tayal A, Cerejo R, Malhotra K, Chandra R, Saini H   +4 more
core